23:04 , Mar 7, 2017 |  BC Week In Review  |  Company News

Neurovance, Otsuka deal

Otsuka will acquire Neurovance for $100 million up front and up to $150 million in development and sales milestones. Milestones can be triggered by clinical trial results, development of a once-daily formulation of Neurovance’s centanafadine...
22:25 , Mar 3, 2017 |  BC Extra  |  Company News

Otsuka acquiring ADHD company Neurovance

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) will acquire ADHD play Neurovance Inc. (Cambridge, Mass.) for $100 million up front and up to $150 million in milestones. The deal gives Otsuka rights to centanafadine (CFR; EB-1020...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Clinical News

Centanafadine SR: Phase IIb data

A double-blind, crossover, U.S. Phase IIb trial in 85 adults with ADHD showed that twice-daily 400 mg oral centanafadine SR met the primary endpoint of improving ADHD-RS-IV total score from baseline to week 3 vs....
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

Centanafadine SR: Phase IIb started

Neurovance began a double-blind, placebo-controlled, crossover, U.S. Phase IIb trial to evaluate oral centanafadine SR starting at 100 mg twice daily titrated up to 400 mg twice daily in about 60 adults with ADHD. Neurovance...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Clinical News

EB-1020 SR: Interim Phase IIa data

Interim data from the single-blind, U.S. Phase IIa EB-1020-ADHD-201 trial in 40 adult male ADHD patients showed that 150-250 mg doses of twice-daily EB-1020 SR significantly improved ADHD-RS-IV score by 22.4 points at week 4...
07:00 , Sep 30, 2013 |  BC Week In Review  |  Clinical News

EB-1020 SR: Phase IIa started

Neurovance began the single-blind, U.S. Phase IIa EB-1020-ADHD-201 trial to evaluate 300-500 mg EB-1020 SR daily for 4 weeks in about 40 adult male ADHD patients. Neurovance Inc. , Cambridge, Mass.   Product: EB-1020 SR...